4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Neuphoria Therapeutics Inc. (NEUP) operates in the Biotechnology industry and is headquartered in Burlington, United States with about 7 employees. Its market capitalization is roughly $18 million.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia.
Interactive charts & full statements → Open the NEUP valuation workbench →
| Income statement | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Revenue | — | $0M | $0M | $0M |
| Operating Income (EBIT) | — | ($18M) | ($22M) | ($15M) |
| Net Income | — | ($16M) | ($21M) | ($15M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $15M | $1M |
| Operating Income (EBIT) | ($1M) | ($2M) | ($6M) | $12M | ($3M) |
| Net Income | ($0M) | $2M | ($10M) | $11M | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|
| Total Assets | $28M | $29M | $45M |
| Total Liabilities | $10M | $7M | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NEUP viewer.
About TickerBase · Data methodology & sources